VI-TWEL
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1949
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VI-TWEL is a small-molecule injectable product approved by Bayer in 1949 with an unknown mechanism of action and indication profile. The product's exact therapeutic use and pharmacological class remain unspecified in available data. This legacy drug represents a historical pharmaceutical asset with limited contemporary clinical characterization.
LOE Approaching
Approaching loss of exclusivity with minimal linked job opportunities suggests a small, legacy-focused team preparing for generic entry or brand sunsetting.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
VI-TWEL currently has zero linked job postings, reflecting its LOE-approaching status and minimal active commercial investment. Career opportunity on this asset is extremely limited and transitional in nature.
Brand ManagerField Sales Representative
Worked on VI-TWEL at Bayer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.